CLDN18.2 ADC Improves Survival in Later Line Gastric Cancer
The randomized 464-patient G-HOPE-001 trial of Innovent-originated, Takeda-licensed arcotatug tavatecan met both overall survival and progression-free survival endpoints against physician’s-choice chemotherapy in CLDN18.2-positive advanced gastric or gastroesophageal junction cancer. The mature overall-survival result is…
